Serious Risks Uncovered in Popular Weight-Loss Drugs
Submitted by MAGA
Posted 3 days ago
DANGER
A new study has revealed alarming health risks associated with the popular diabetes and weight-loss drugs, Ozempic and Wegovy, which have seen a meteoric rise in prescriptions over recent years.
The drugs, both containing the active ingredient semaglutide, are now linked to a significantly increased risk of a rare form of blindness known as nonarteritic anterior ischemic optic neuropathy (NAION).
This disturbing development adds to the already extensive list of potential side effects, which includes depression, kidney failure, and even thyroid cancer.
Health experts point out that the risk of NAION has more than doubled in patients using these medications weekly.
Patients suffering from this condition may experience sudden vision loss, with many not realizing the connection until it's too late.
The revelation raises serious questions about the transparency of pharmaceutical companies and the regulatory framework that governs drug safety in the U.S.
It’s essential to acknowledge that many risks associated with new medications may not be fully understood until extensive long-term studies are conducted.
Given the significant advertising campaigns surrounding these drugs, one can’t help but wonder if the public has been adequately informed about the genuine dangers.
This situation echoes a long-standing pattern seen with major drug companies, which can often prioritize profits over public health.
Perhaps most concerning is the fact that these risks are not widely covered in mainstream media, leading many patients to remain in the dark about the potential consequences of long-term use.
Prescribing physicians must be vigilant and ensure their patients possess all the relevant information to make informed decisions about their health.
More scrutiny from the FDA and improved reporting requirements for adverse drug reactions are urgently needed to safeguard the public from potential pharmaceutical pitfalls.
As more Americans turn to these weight-loss solutions, it is crucial to emphasize that consumers deserve full transparency regarding the medications they are prescribed.
Health decisions should not be based on trendy treatments promoted by pharmaceutical companies, but rather on reliable, thorough research and holistic approaches to well-being.
The costs of overlooking potential risks can be steep, and it is paramount that patients are empowered to make choices that prioritize their health above all else.
Sources:
rumble.com
sharylattkisson.com
theblaze.com
A new study has revealed alarming health risks associated with the popular diabetes and weight-loss drugs, Ozempic and Wegovy, which have seen a meteoric rise in prescriptions over recent years.
The drugs, both containing the active ingredient semaglutide, are now linked to a significantly increased risk of a rare form of blindness known as nonarteritic anterior ischemic optic neuropathy (NAION).
This disturbing development adds to the already extensive list of potential side effects, which includes depression, kidney failure, and even thyroid cancer.
Health experts point out that the risk of NAION has more than doubled in patients using these medications weekly.
Patients suffering from this condition may experience sudden vision loss, with many not realizing the connection until it's too late.
The revelation raises serious questions about the transparency of pharmaceutical companies and the regulatory framework that governs drug safety in the U.S.
It’s essential to acknowledge that many risks associated with new medications may not be fully understood until extensive long-term studies are conducted.
Given the significant advertising campaigns surrounding these drugs, one can’t help but wonder if the public has been adequately informed about the genuine dangers.
This situation echoes a long-standing pattern seen with major drug companies, which can often prioritize profits over public health.
Perhaps most concerning is the fact that these risks are not widely covered in mainstream media, leading many patients to remain in the dark about the potential consequences of long-term use.
Prescribing physicians must be vigilant and ensure their patients possess all the relevant information to make informed decisions about their health.
More scrutiny from the FDA and improved reporting requirements for adverse drug reactions are urgently needed to safeguard the public from potential pharmaceutical pitfalls.
As more Americans turn to these weight-loss solutions, it is crucial to emphasize that consumers deserve full transparency regarding the medications they are prescribed.
Health decisions should not be based on trendy treatments promoted by pharmaceutical companies, but rather on reliable, thorough research and holistic approaches to well-being.
The costs of overlooking potential risks can be steep, and it is paramount that patients are empowered to make choices that prioritize their health above all else.
Sources:
rumble.com
sharylattkisson.com
theblaze.com
Latest News